Verseau Therapeutics
PrivateLast Round
Series B
Oct 21, 2019
Total Funding Raised
$104.3M
Company Overview
Verseau Therapeutics operates in Healthcare & Life Sciences and is based in Auburndale, Florida. Its latest recorded funding round was a Series B round in October 2019.
Verseau Therapeutics is a biotechnology company that develops macrophage checkpoint modulators to treat cancer and immune-related inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Verseau Therapeutics Comparables
Compare Verseau Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DEM BioPharma | 85% | |
| Immune-Onc Therapeutics | 82% | |
| OncoResponse | 80% |
For institutional investors. Book with your work email.
Verseau Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 21, 2019 | ||||
| Series B | Feb 12, 2019 |
For institutional investors. Book with your work email.
Verseau Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series B |
| Highlight Capital | Series B |
| Yonghua Capital | Series B |
| The Mark Foundation for Cancer Research | Series B, Series A |
| Alexandria Venture Investments | Series B |
| 20/20 HealthCare Partners | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 12, 2019
$50M raised from Alexandria Venture Investments and Yonghua Capital.
For institutional investors. Book with your work email.
Verseau Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Verseau Therapeutics's valuation, stock price, and market status.
Is Verseau Therapeutics a public or private company?
Verseau Therapeutics is a private company.
What is the current stock price of Verseau Therapeutics?
Verseau Therapeutics is a private company, so its shares have no public market price. Caplight tracks Verseau Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Verseau Therapeutics worth (valuation)?
Valuation information for Verseau Therapeutics is not publicly available.
Can I buy Verseau Therapeutics stock?
Verseau Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Verseau Therapeutics's last funding round?
Verseau Therapeutics's most recent funding round was Series B on October 21, 2019.
Who are the main investors in Verseau Therapeutics?
Key investors in Verseau Therapeutics include 20/20 HealthCare Partners.
Will Verseau Therapeutics IPO soon?
No public IPO plans have been announced for Verseau Therapeutics.
How can I track Verseau Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Verseau Therapeutics's shares on secondary markets.